Biostar Pharm-B Calls 26 Jun 2026 AGM: No 2025 Dividend, New Share Option Scheme, Board Refresh & Dual Mandates

Biostar Pharm-B (02563) has issued a circular convening its annual general meeting for 26 Jun 2026 in Beijing.

Key proposals to be put before shareholders include:

• 2025 Financials & Dividend – The board will seek approval of the audited 2025 results and confirm that no final dividend is proposed as the company posted a net loss for the year.

• Capital Mandates – Directors request:  – A general mandate to issue up to 20% of the existing share capital (maximum 72.92 million shares) over the coming year.  – An H-share repurchase mandate covering up to 10% of issued H shares (36.46 million shares).

• Share Option Scheme – Adoption of a new 10-year option plan covering up to 10% of issued H shares. Options will vest over at least 12 months, be performance-linked and carry an exercise price no lower than the higher of (i) the closing price on the grant date, (ii) the average closing price of the five preceding trading days, or (iii) the nominal value. A sub-limit of 2% applies to service-provider grantees and 1% individual ceiling applies within any 12-month period.

• Governance Changes – Plan to abolish the Supervisory Committee and transfer its oversight duties to the board’s Audit Committee, alongside amendments to the Articles of Association.

• Board & Auditor – Appointment of Dr Zhu Xiaodong as independent non-executive director with an annual fee of RMB0.15 million, and re-appointment of WUYIGE Certified Public Accountants LLP as auditor for 2026. Directors’ remuneration for 2026 will be capped at 120% of 2025 levels.

• Connected Transactions – Shareholders will be asked to ratify related-party dealings undertaken during 2025.

Shareholder Logistics The register of members will close from 23 to 26 Jun 2026 (both days inclusive). Proxy forms must be lodged by 3:00 p.m. on 25 Jun 2026.

If all resolutions pass, the board gains flexibility for capital management, introduces long-term incentives aligned with performance, updates governance in line with the amended PRC Company Law and optimises board composition ahead of the next phase of growth.